Narrative review of preclinical TCM mechanisms in skin aging
This narrative review summarizes preclinical studies of traditional Chinese medicine (TCM) botanical drugs and formulae in skin aging, reporting antioxidant, anti-inflammatory and collagen-preserving effects; clinical evidence is described as extremely limited. [1]
Automatic summary · not editorially reviewed
The key findings
The review identified 19 single-botanical drug studies and 17 formula studies on TCM in skin aging. [1]
Reported effects included Nrf2/ARE activation, lower reactive oxygen species and malondialdehyde, higher superoxide dismutase activity, matrix metalloproteinase inhibition and lower senescence markers. [1]
No adequately powered, preregistered, high-quality randomized controlled trial has yet established clinical efficacy for TCM in skin aging. [1]
The source at a glance
- Study type / format
- Narrative review (abstract)
- Population / context
- Preclinical studies of TCM botanical drugs and formulae in skin aging, plus small human studies
- Summary based on
- Study abstract
- Original publication
- August 19, 2026
Preclinical TCM studies on skin aging pathways
The review describes skin aging as involving complex endogenous and extrinsic mechanisms, including oxidative stress, cellular senescence, DNA damage and degradation of the extracellular matrix. It synthesizes preclinical evidence on TCM-derived botanical drugs and formulae targeting these pathways. The authors identified 19 studies of single botanical drugs and 17 studies of formulae.
Supporting source [1]
Reported antioxidant, MMP and senescence marker effects
The most consistently reported effects were activation of Nrf2/ARE, reduced reactive oxygen species and malondialdehyde, increased superoxide dismutase activity, inhibition of matrix metalloproteinases and lower senescence markers (p16, p21 and senescence-associated β-galactosidase). Other modulated pathways included MAPK/AP-1, PI3K/Akt/mTOR, TGF-β/Smad and NAD+/Sirtuin, together linked to reduced inflammation, enhanced antioxidant defense and preserved dermal collagen. The authors interpret this as multi-pathway modulation rather than true pharmacological synergy.
Supporting source [1]
Limited clinical evidence and proposed research priorities
The review states that clinical evidence remains extremely limited and consists mainly of small human studies, including trials described as randomized or double-blind but incompletely reported, and single-arm evaluations. No adequately powered, preregistered, high-quality randomized controlled trial has yet established clinical efficacy for TCM interventions in skin aging. The authors therefore propose prioritizing rigorous randomized controlled trials, dose-response designs and phytochemical standardization.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. The review is narrative and synthesizes preclinical evidence; clinical evidence is described as extremely limited, with small, incompletely reported or single-arm human studies. Reported pathway effects are associations in preclinical models, not established clinical benefits.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Yin S, Zheng H, Yang Q, Chen X, Yang Q, Yang Q, Cheng H, Wu J. · europepmc.org · August 19, 2026